Page 17 - Biomedicine

to that in advanced countries in Europe and America. Besides, the abundant practical
experience in clinical trials as well as strong capabilities are also the reasons why
Taiwan attracts such investment. Merck of Germany and Pzer and Johnson & Johnson
of the US, among others, have also established clinical trial or related collaborative
mechanisms with medical or R&D institutions in Taiwan, such as Veterans General
Hospitals, China Medical University, National Taiwan University, the Industrial
Technology Research Institute, and many others, which is conducive to them
conducting international/cross-regional clinical trials.

2 Manufacturing and production

Pzer is not only the rst foreign pharmaceutical company, but also the largest
one in Taiwan. Its products cover cardiovascular disease, the urinary system, vaccines,
antibiotics/antifungal/antivirals, pain, cancer, cerebral neurological system, vision care,
endocrine system, smoking cessation, female health, hemophilia, immune system,
gastrointestinal system, anesthesia, and antidotes.

Collaboration in technical
3
research and development

Impressed by the R&D capability of the biotechnology and medical device
sectors in Taiwan and the associated business opportunities on the market, Denka, the
leader in clinical laboratory tests and u vaccines in Japan, formed a strategic alliance
with PlexBio, the precision medicine molecular test technical platform developer in
Taiwan, in September 2019. They will collaborate in the field of in-vitro diagnostic
ecology. Once product technologies are mature, besides highly sophisticated medical
tests, the applications may be extended to animals, plants, and foods, among other life
science domains. The business opportunities on the market are huge.

15